Loading clinical trials...
Loading clinical trials...
A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Subjects With Advanced Solid Tumors
Conditions
Interventions
Evixapodlin
Locations
6
United States
California Care Associates for Research and Excellence Inc
Encinitas, California, United States
NEXT Oncology
San Antonio, Texas, United States
Northwest Medical Specialties, PLLC
Tacoma, Washington, United States
Auckland City Hospital
Auckland, New Zealand
Christchurch Clinical Studies Trust, LLC
Christchurch, New Zealand
Auckland Clinical Studies Ltd
Grafton, Auckland, New Zealand
Start Date
August 26, 2019
Primary Completion Date
March 30, 2021
Completion Date
March 30, 2021
Last Updated
October 6, 2022
NCT07177937
NCT07387068
NCT07360314
NCT07539285
NCT07403721
NCT07524348
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions